IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma

Yan Zhu; Lawrence N. Kwong

doi:10.1158/2159-8290.CD-21-1643

IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma

Yan Zhu, Lawrence N. Kwong

Translational Molecular Pathology

Research output: Contribution to journal › Article › peer-review

Abstract

Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma, but their exact mechanisms in cholangiocarcinoma initiation and maintenance are unclear. In this issue of Cancer Discovery, Wu and colleagues identify immune suppression via TET2 inactivation as the primary means by which mIDH1 maintains cholangiocarcinoma survival, leading to an efficacious new combination of mIDH1 inhibitors and immune checkpoint blockade targeting regulatory T cells.

Original language	English (US)
Pages (from-to)	604-605
Number of pages	2
Journal	Cancer discovery
Volume	12
Issue number	3
DOIs	https://doi.org/10.1158/2159-8290.CD-21-1643
State	Published - Mar 1 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-21-1643

Cite this

@article{f203051af2aa4c17a15067b79ef6bd76,

title = "IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma",

abstract = "Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma, but their exact mechanisms in cholangiocarcinoma initiation and maintenance are unclear. In this issue of Cancer Discovery, Wu and colleagues identify immune suppression via TET2 inactivation as the primary means by which mIDH1 maintains cholangiocarcinoma survival, leading to an efficacious new combination of mIDH1 inhibitors and immune checkpoint blockade targeting regulatory T cells.",

author = "Yan Zhu and Kwong, {Lawrence N.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",

year = "2022",

month = mar,

day = "1",

doi = "10.1158/2159-8290.CD-21-1643",

language = "English (US)",

volume = "12",

pages = "604--605",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

TY - JOUR

T1 - IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma

AU - Zhu, Yan

AU - Kwong, Lawrence N.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma, but their exact mechanisms in cholangiocarcinoma initiation and maintenance are unclear. In this issue of Cancer Discovery, Wu and colleagues identify immune suppression via TET2 inactivation as the primary means by which mIDH1 maintains cholangiocarcinoma survival, leading to an efficacious new combination of mIDH1 inhibitors and immune checkpoint blockade targeting regulatory T cells.

AB - Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma, but their exact mechanisms in cholangiocarcinoma initiation and maintenance are unclear. In this issue of Cancer Discovery, Wu and colleagues identify immune suppression via TET2 inactivation as the primary means by which mIDH1 maintains cholangiocarcinoma survival, leading to an efficacious new combination of mIDH1 inhibitors and immune checkpoint blockade targeting regulatory T cells.

UR - http://www.scopus.com/inward/record.url?scp=85125971442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125971442&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-21-1643

DO - 10.1158/2159-8290.CD-21-1643

M3 - Article

C2 - 35257150

AN - SCOPUS:85125971442

SN - 2159-8274

VL - 12

SP - 604

EP - 605

JO - Cancer discovery

JF - Cancer discovery

IS - 3

ER -

IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this